ACT AlzChem Group

DGAP-News: AlzChem Group AG: sales in the 9-month period of 2020 slightly declining, EBITDA stable

DGAP-News: AlzChem Group AG / Key word(s): 9 Month figures
AlzChem Group AG: sales in the 9-month period of 2020 slightly declining, EBITDA stable

11.11.2020 / 07:00
The issuer is solely responsible for the content of this announcement.


Trostberg, November 11, 2020 - AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, generated consolidated sales of EUR 278.6 million in the first nine months of fiscal year 2020, compared to EUR 287.7 million in the 9-month period of 2019. The slight growth in the Specialty Chemicals segment was offset by a stronger overall decline in the Basics & Intermediates and Other & Holding segments. Here, the effects of the COVID-19 pandemic became particularly apparent in the 3rd quarter of 2020. Volumes for the metallurgy and automotive sectors were particularly affected. Nevertheless, high diversification with a very broad product base remains the unique selling point and stable backbone of the AlzChem Group, because on the one hand it secures the sales development in this challenging environment on the downside and on the other hand it offers significant future potential. It should also be emphasized that the supply chain was kept stable throughout, thus ensuring unrestricted production operations throughout the entire 9-month period of 2020.

The earnings performance in the reporting period was satisfactory overall. Despite the slight decrease in sales, consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 41.1 million reached the previous year's level of EUR 41.4 million, equivalent to an EBITDA margin of 14.8% (9M 2019: 14.4%). The lower raw material prices and the effects of the programs for digitization and process and cost optimization had a particularly positive impact here, which together led to a significant reduction in the cost of materials ratio from 39% to 36%. Depreciation and amortization increased as planned by EUR 3.4 million due to the investments and completion of new plants at the end of the previous year. Overall, this results in a consolidated result for the first nine months of 2020 of EUR 14.0 million after EUR 17.0 million in the prior-year period.

Cash flow from operating activities developed very pleasingly in the 9-month period of 2020. Cash inflow from operating activities amounted to EUR 33.8 million, an increase of EUR 8.2 million over the previous year. Despite a lower consolidated result for the period, it was possible to generate significant cash and cash equivalents, particularly through efficient working capital management.

For the full year 2020, the Management Board expects a stable to slightly declining development of consolidated sales and a stable to moderately declining adjusted EBITDA due to the ongoing effects of the COVID-19 pandemic in individual target industries and regions.

The detailed quarterly statement for the 3rd quarter of 2020 is available for download on the website under

About AlzChem
The AlzChem Group is a vertically integrated manufacturer of chemical products based on the so-called NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The Group has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,620 employees at four sites in Germany and three other sites abroad.




Contact:
Sabine Sieber
Head of Investor Relations & Communications
T 8
F 888


11.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: AlzChem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone:
Fax:
E-mail:
Internet:
ISIN: DE000A2YNT30
WKN: A2YNT3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 1147130

 
End of News DGAP News Service

1147130  11.11.2020 

fncls.ssp?fn=show_t_gif&application_id=1147130&application_name=news&site_id=research_pool
EN
11/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlzChem Group

Peter Thilo Hasler
  • Peter Thilo Hasler

Zum Halbjahr neue Höchstwerte bei Umsatz und Marge

Während das Basissegment Basics & Intermediates erwartungsgemäß rückläufig war (H1/2025 Umsatz EUR 78,2 Mio., -14,2% YoY), verzeichnete das margenträchtige Segment Specialty Chemicals im ersten Halbjahr 2025 ein Umsatzplus von 8,9% auf EUR 194,6 Mio. – getragen von einem Nachfrageaufschwung im Bereich Custom Manufacturing sowie einem weiterhin starken Geschäft mit Creapure im Bereich Human Nutrition. Der Umsatzanteil des Segments liegt mittlerweile bei 67,7% – Tendenz steigend und ist damit nach...

Peter Thilo Hasler
  • Peter Thilo Hasler

Weiterhin mit robustem Gewinnwachstum

Nach wie vor ist die Ertragsentwicklung von Alzchem von konjunkturellen Herausforderungen geprägt, profitiert aber in ungleich stärkerem Maße von der Verschiebung des Umsatz-Mix in das hochmargige Segment Specialty Chemicals. Weil deshalb die vorgelegten Zahlen zum ersten Quartal 2025 erneut über unseren Schätzungen sowie den Consensus-Erwartungen lagen und wir davon ausgehen, dass die höhermargigen Potenziale weiterhin abgeschöpft werden können, heben wir unser aus einem dreiphasigen DCF-Entity...

 PRESS RELEASE

EQS-News: Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung...

EQS-News: Alzchem Group AG / Schlagwort(e): Aktienrückkauf/Aktienrückkauf Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052 - Zeitweilige Unterbrechung des Aktienrückkaufprogramms 17.03.2025 / 11:38 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Alzchem Group AG   Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052       Trostberg, 17. März 2025   Zeitweilige Unterbrechung de...

 PRESS RELEASE

EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the ...

EQS-News: Alzchem Group AG / Key word(s): Share Buyback/Share Buyback Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - Temporary Interruption of Share Repurchase Prog 17.03.2025 / 11:38 CET/CEST The issuer is solely responsible for the content of this announcement. Alzchem Group AG   Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, March 17, 2025   Temporary Inter...

Peter Thilo Hasler
  • Peter Thilo Hasler

Von hohem Niveau aus weiter aufwärts

Dass Alzchem auch im vierten Quartal 2024 sowohl die eigene Guidance als auch alle Consensus-Prognosen übertraf, kann aus unserer Sicht nicht als Normalität eingestuft werden. Kritisch ließe sich einwenden, dass die Luft angesichts des inzwischen erreichten Margenniveaus dünner wird, doch lässt die anhaltende Verschiebung zum höhermargigen Segment Specialty Chemicals nach unserer Auffassung einen erneuten Margenanstieg und einen damit einhergehenden überproportionalen Ergebnisanstieg auch im Ges...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch